http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1346037-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6382e2e3b089a524e41b2041d0c58caa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-50 |
| filingDate | 1972-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1974-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1346037-A |
| titleOfInvention | 2-(indanyl-4 2-amino)-delta 2 imidazoline and its salts processes for producing the same and pharmaceutical compositions containing the same |
| abstract | 1346037 2 - (Indanyl - 4<SP>1</SP> amino) - #<SP>2</SP>- imidazoline NORDMARK-WERKE GmbH 18 July 1972 [21 July 1971] 33461/72 Heading C2C 2 - (Indanyl - 41 - amino) - #<SP>2</SP> - imidazoline and its acid addition salts, are prepared (1) by reacting a compound II in which R is or CN where R 1 is C 1-6 alkyl with ethylene diamine or a monosalt thereof (2) subjecting N-(4-indanyl)-N<SP>1</SP>-(#-aminoethyl) urea or thiourea to ring closure by heating to a temperature between 130-200‹ C. C. (3) reacting 4-aminoindene with a compound (V) in which R 1 is C 1-6 alkyl or with bis-(2-oxo-1- imidazoledinyl)phosphuryl chloride (4) reacting an indenyl-4-isocyanide dihalogenide in which the halogen in chlorine or bromine with ethylene diamine or (5) partially hydrogenating 2-(indenyl - 41 - amino) - #<SP>2</SP> - imidazoline either with a catalyst (Raney-Nickel) at elevated temperature and pressure or using nascent hydrogen. 2 - (Indenyl - 41 - amino) - #<SP>2</SP> - imidazoline and its acid-addition salts possess vasoconstrictor properties and form with a carrier or diluent a pharmaceutical composition. |
| priorityDate | 1971-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.